Verona Pharma plc Verona Pharma To Announce Operational Update And Financial Results For First Quarter Ended March 31, 2018

 
TIDMVRP 
 
 
   LONDON, May 02, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that it will report its audited 
financial results for the first quarter ended March 31, 2018 on Tuesday, 
May 8, 2018. 
 
   Verona Pharma will host an investment community conference call at 9:00 
a.m. Eastern Daylight Time (2:00 p.m. British Summer Time) on Tuesday, 
May 8, 2018 to discuss the first quarter financial results and provide a 
clinical development update. 
 
   Analysts and investors may participate in the conference call by 
utilizing the conference ID: 3853885 and dialing the following numbers: 
 
 
   -- 888-394-8218 or [phone] for callers in the United States 
 
   -- 0800 279 7204 or 44 (0)330 336 9411 for callers in the United Kingdom 
 
   -- 0800 101 1732 or 49 (0)69 2222 2018 for calls in Germany 
 
 
   Those interested in listening to the conference call live via the 
internet may do so by visiting the "Investors" page of Verona Pharma's 
website at www.veronapharma.com and clicking on the "Events and 
presentations" link. 
 
   A webcast replay of the conference call (audio) will be available for 30 
days on the "Investors" page of Verona Pharma's website at 
www.veronapharma.com. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual 
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a 
bronchodilator and an anti-inflammatory agent in a single compound. In 
clinical trials, treatment with RPL554 has been observed to result in 
statistically significant improvements in lung function as compared to 
placebo, and has shown clinically meaningful and statistically 
significant improvements in lung function and clinical symptoms as 
compared to placebo, and has shown statistically significant 
improvements in lung function when administered in addition to 
frequently used short- and long-acting bronchodilators as compared to 
such bronchodilators administered as a single agent. Verona Pharma is 
developing RPL554 for the treatment of chronic obstructive pulmonary 
disease (COPD), cystic fibrosis (CF), and potentially asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: [phone] 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison   [e-mail] 
 
FTI Consulting (UK Media and Investor enquiries)   Tel: [phone] 
Simon Conway / Natalie Garland-Collins             [e-mail] 
 
ICR, Inc. (US Media and Investor enquiries) 
James Heins                                        Tel: [phone] 
                                                    [e-mail] 
Stephanie Carrington                               Tel. [phone] 
                                                    [e-mail] 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

May 02, 2018 08:30 ET (12:30 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.